Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro - PubMed (original) (raw)
. 1995 Nov 15;55(22):5330-4.
Affiliations
- PMID: 7585596
Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
A B Bakker et al. Cancer Res. 1995.
Abstract
MHC class I-restricted CTLs specific for antigens expressed by malignant cells are an important component of immune responses against human cancer. Recently, in melanoma a number of melanocyte differentiation antigens have been identified as potential tumor rejection antigens. In the present study, we show that by applying peptide-loaded dendritic cells, induced by granulocyte-macrophage colony-stimulating factor and interleukin 4 from peripheral blood monocytes of healthy donors, we were able to elicit melanoma-associated antigen-specific CTL in vitro. We demonstrate the induction of CTLs directed against HLA-A2.1 presented epitopes derived from tyrosinase, gp100, and Melan A/MART-1. Apart from lysis of peptide-loaded target cells, these CTLs displayed reactivity with HLA-A2.1+ melanoma tumor cell lines and cultured normal melanocytes endogenously expressing the target antigen. These data indicate that these CTLs recognize naturally processed and presented epitopes and that precursor CTLs against melanocyte differentiation antigens are present in healthy individuals. The ability to generate tumor-specific CTLs in vitro, using granulocyte-macrophage colony-stimulating factor/interleukin 4-induced dendritic cells, illustrates the potential use of this type of antigen-presenting cells for vaccination protocols in human cancer.
Similar articles
- Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.
Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Kärre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R. Salazar-Onfray F, et al. Cancer Res. 1997 Oct 1;57(19):4348-55. Cancer Res. 1997. PMID: 9331097 - Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Salgaller ML, et al. Cancer Res. 1995 Nov 1;55(21):4972-9. Cancer Res. 1995. PMID: 7585538 - The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes.
Kirkin AF, Dzhandzhugazyan K, Zeuthen J. Kirkin AF, et al. Exp Clin Immunogenet. 1998;15(1):19-32. doi: 10.1159/000019050. Exp Clin Immunogenet. 1998. PMID: 9619397 Review. - [Analysis of tumor rejection antigen peptides recognized by specific CTL].
Uenaka A, Nakayama E. Uenaka A, et al. Nihon Rinsho. 1996 Jan;54(1):242-9. Nihon Rinsho. 1996. PMID: 8587197 Review. Japanese.
Cited by
- Melanoma vaccines: clinical status and immune endpoints.
Maurer DM, Butterfield LH, Vujanovic L. Maurer DM, et al. Melanoma Res. 2019 Apr;29(2):109-118. doi: 10.1097/CMR.0000000000000535. Melanoma Res. 2019. PMID: 30802228 Free PMC article. - Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H. Chheda ZS, et al. J Exp Med. 2018 Jan 2;215(1):141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4. J Exp Med. 2018. PMID: 29203539 Free PMC article. - Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
Fecek RJ, Storkus WJ. Fecek RJ, et al. Immunotherapy. 2016 Oct;8(10):1205-18. doi: 10.2217/imt-2016-0071. Immunotherapy. 2016. PMID: 27605069 Free PMC article. Review. - Cancer vaccines.
Butterfield LH. Butterfield LH. BMJ. 2015 Apr 22;350:h988. doi: 10.1136/bmj.h988. BMJ. 2015. PMID: 25904595 Free PMC article. Review. - An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.
Schaft N, Coccoris M, Drexhage J, Knoop C, de Vries IJ, Adema GJ, Debets R. Schaft N, et al. Front Immunol. 2013 Sep 4;4:270. doi: 10.3389/fimmu.2013.00270. eCollection 2013. Front Immunol. 2013. PMID: 24027572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials